Akero shares double after preliminary results from mid-stage trial for liver disease drug
ReutersJan 27, 2025 11:48 AM
Jan 27 (Reuters) - Akero Therapeutics AKRO.O shares gained 106% before the bell on Monday after the company reported results from a mid-stage trial studying its lead drug in patients with a type of liver disease.
The experimental drug efruxifermin is being studied in patients with scarring due to a type of fatty liver disease known as metabolic dysfunction-associated steatohepatitis.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Nvidia Q2 Earnings Expectations: With Little Room for Error, Will China-Related Risks Be Magnified?
TradingKey - Ahead of Nvidia Q2 FY2026 earnings report, multiple Wall Street firms have raised their price targets on Nvidia, reflecting strong confidence in AI demand. While analysts continue to forecast robust ~50% year-over-year growth in revenue and EPS, the China variable remains a major riskTradingKey
14 hours ago
Trump to Sack Cook: Why the Fed Must Maintain Its Independence?
TradingKey - On 25 August 2025, Trump announced the immediate dismissal of Cook from her position as a Federal Reserve Governor, citing "false statements in mortgage loan documents." On the surface, this appears to be an action targeting an individual official's conduct.TradingKey
15 hours ago
What to Watch in Nvidia’s Q2 FY2026 Earnings: AI Growth, Margins, and Market Impact
TradingKey - NVIDIA Corporation (NASDAQ: NVDA) will report its Q2 FY2026 earnings on Wednesday, August 27, 2025, after the U.S. market closes. The earnings call is scheduled for 5:00 p.m. Eastern Time. With Nvidia being a bellwether in AI, gaming, and data center markets, and carrying significant...TradingKey
Mon, Aug 25
Eurozone Q2 GDP Commentary: Will the Euro's Upward Momentum Persist?
TradingKey - On 14 August 2025, Eurostat published Q2 GDP figures, revealing a drop in the Eurozone's quarter-on-quarter growth from 0.6% in the first quarter to 0.1%. Consequently, annual growth eased from 1.5% to 1.4%. The slowdown primarily stems from the diminishing boost from European...TradingKey
Mon, Aug 18
Ethereum Price Prediction: Will ETH Extend the Rally? What’s the Future Trend?
Ethereum's impressive 2025 rally has been largely fueled by inflows from spot ETFs and a surge in institutional holdings, signaling growing confidence in its role as a core asset in the crypto market. However, to officially confirm the start of a new bull cycle, ETH must break above the critical $4,TradingKey
Wed, Jul 23
